Analysis snapshotSnapshot decision:BUY

PacBio Sequel IIe Sequencer — Auction Analysis

A 2021 PacBio Sequel IIe closed with a $25 winning-bid observation, but unknown deficiencies, no functional evidence, 798 lb removal, software/infrastructure uncertainty, and a 2028 support sunset leave only a roughly $50 blind hammer ceiling.

Analysis snapshot · Historical — observed August 29, 2026. The source records a closing high bid, but award or settlement is not independently established. The original observed price, evidence, economics, and recommendation remain exactly as recorded and are not current.

Decision at a glance

RecommendationBUY
Maximum hammer bid
$50

The auction bid ceiling supported by this analysis, if one is defensible; see costs below for buyer-premium treatment.

Why this decision

BUY only at or below the roughly $50 blind ceiling: the $25 closing high / winning-bid observation is below it, but removal, specialist verification, unknown deficiencies, and serviceability can eliminate the margin.

See costs and maximum bid for the displayed assumptions and buyer-premium treatment.

Closing high bid
$25
Bidders
1
Blind-model resale
$7,000
Snapshot provenance and timing · observed August 29, 2026 · scheduled close August 12, 2026

GSA Auctions sale 3-1-QSC-I-26-508, lot 032 · Kerrville, Texas
Snapshot observed August 29, 2026
Scheduled close August 12, 2026
Analysis prepared August 29, 2026
Published August 29, 2026 · page updated August 29, 2026

Prepared and published by Oleksii Udod for LotCaliper.

Continue after this auction

This auction snapshot is historical. Continue with related research, or review a relevant published analysis whose recorded scheduled close has not passed.

These are individually prepared, time-stamped analyses with recorded scheduled closes. Verify the official auction before acting.

Auction snapshot

At the August 29, 2026 historical review, detailed bid history showed a $25 closing high / winning-bid observation with one bidder. It does not prove payment, award, pickup, or final settlement.

A high original capital-equipment price does not make an untested specialist platform an arbitrage: lifecycle, functional state, support, logistics, and a complete workflow determine resale value.

Review and correction history

Independent review not recorded for this legacy analysis. No corrections recorded.

View review and correction details

Independent review not recorded

Published before the current independent-review gate; no completed independent review is recorded.

How independent review works
How evidence is classified

Seller facts, photo-derived observations, manufacturer context, unknowns, and LotCaliper assumptions remain explicitly separated.

Source Confirmed

Seller-confirmed

  • One 2021 PacBio Sequel IIe, part number 101-986-400; the plate identifies research-use-only equipment.
  • Seller says the unit was replaced because it was outdated and warns that parts may be missing, repairs may be required, and deficiencies are unknown.
  • $25 detailed closing high / winning-bid observation with one bidder.

Photo Derived

Photo-derived

  • Main cabinet, touchscreen, exterior panels, and manufacturer plate are visible; no obvious catastrophic exterior impact is visible.
  • Nearby racks, boxes, and facility infrastructure are not treated as included.

Not Established

Not established

  • Power-on, diagnostics, sequencing performance, internal completeness, or a second-owner recommissioning path.
  • Software entitlement, compute/storage, UPS, nitrogen equipment, consumables, service contract, and any ancillary equipment.

Manufacturer Context

Independent context

  • PacBio says Sequel IIe sales ended November 28, 2025 and Sequel II/IIe support ends September 30, 2028.
  • PacBio documentation lists roughly 798 lb / 362 kg, 208–240 VAC / 30 A, cooling, nitrogen, and SMRT Link workflow context.

Lotcaliper Assumption

LotCaliper assumptions

  • $7,000 conservative gross resale after verification; approximately $2,000–$10,000 broader specialist range.
  • $4,500 non-acquisition burden excluding selling fees and hammer; ~$50 blind maximum hammer.

Equipment identity

Laboratory · quantity 1

PacBio / Pacific Biosciences Sequel IIe, part number 101-986-400

Identity confidence: High

Identity evidence
  • Seller evidence and manufacturer plate establish one 2021 PacBio Sequel IIe, part number 101-986-400.

    GSA Auctions · Image · observed August 29, 2026

Configuration

Main Sequel IIe cabinet, touchscreen, exterior panels, and manufacturer plate

Confirmed · High confidence

Configuration evidence
  • Supplied auction photographs show the main cabinet, touchscreen, panels, and plate.

    GSA Auctions · Image · observed August 29, 2026

Software entitlement, compute/storage environment, UPS, nitrogen equipment, consumables, service contract, and ancillary room equipment

Not established · no source evidence establishes presence or absence

Configuration evidence
  • Auction evidence does not establish a transferable or complete sequencing workflow beyond the main instrument.

    GSA Auctions · Image · observed August 29, 2026

Condition

As-is / repair risk

Seller classifies the instrument as used, warns that parts may be missing and repairs may be required, and says deficiencies are unknown.

Evidence confidence: High

Condition evidence
  • Seller condition statement, paraphrased.

    GSA Auctions · Text · observed August 29, 2026

Untested

No power-on, self-test, sequencing run, or diagnostic result is evidenced; replacement because the unit was outdated is not functional evidence.

Evidence confidence: High

Condition evidence
  • Supplied source record and photographs do not establish functional operation.

    GSA Auctions · Image · observed August 29, 2026

Market evidence

Market evidence strength

Medium

Public auditability

Limited Legacy

Evidence recency

Not Recorded

No structured comparable-evidence metadata was preserved for this dated snapshot. Public auditability is limited; the numeric resale snapshot cannot be independently audited from comparable records on this page.

Legacy evidence counts were not preserved. Unknown is not reported as zero.

Sensitivity and robustness

Survives

The published decision survives the selected downside check under the stated bounded assumptions.

Blind/as-is historical model

Max hammer
$50
Gross resale model
$2,000–$7,000

At the preserved $25 closing high / winning-bid observation, the model produces about $1,425 profit and 31.5% ROI. This is not represented as a settled sale.

Costs and maximum bid

Transaction / operating costAmountBasis
Selling Fees$1,050LotCaliper assumption: 15% of modeled gross resale.
Shipping$2,000LotCaliper pickup, packing, rigging, and inbound-logistics reserve; not a carrier or GSA quote.
Testing Repair Reserve$1,000LotCaliper functional-test and diagnostic reserve.
Risk Buffer$1,500Unknown deficiencies, internal completeness, second-owner serviceability, software/infrastructure, specialist liquidity, and return exposure.
Buyer premium
Not modeled
Return requirements
$500 minimum profit · 30% minimum ROI
Computed bid constraints

Profit floor: $950

ROI floor: $77

Binding: ROI floor

Snapshot blind/as-is max hammer
$50
Modeled result at recorded bid
$1,425 profit · 31.50% modeled ROI

This is a reseller ceiling, not a prediction of the auction's closing price. Any buyer premium or other unquoted acquisition charge must be deducted before bidding.

Lifecycle, workflow, and specialist-removal economics

The strongest realized exact-part-number evidence involved systems in OEM crates, which is materially better preparation than this unknown-deficiency GSA unit. Current asking evidence ranges from low four figures to higher working-state asks, so original list price and dealer asks are not the valuation basis.

The $25 observation is favorable only if professional removal, service, and functional verification can be controlled. A major internal fault, inability to obtain service, or higher removal cost can erase the BUY conclusion.

  • Verify successful boot, diagnostics, control/software state, robotics/fluidics, environmental control, consumables, and a representative sequencing or service diagnostic.
  • Obtain professional removal, packing, freight, and recommissioning quotes before raising a bid materially above the blind ceiling.

Recommendation and rationale

Snapshot decision

BUY

BUY only at or below the roughly $50 blind ceiling: the $25 closing high / winning-bid observation is below it, but removal, specialist verification, unknown deficiencies, and serviceability can eliminate the margin.

Confidence

Identity
High
Configuration
Medium Low
Condition
Low
Market Support
Medium
Costs
Medium Low

Market support assesses how well the available evidence supports the resale assumption. Exact third-party marketplace records may be omitted when source-use rights are unclear. Each dimension uses the published methodology rubric; a confidence label measures the strength and boundedness of its evidence, not the likelihood of a profitable outcome.

Risks and unknowns

High · Functionality Unverified

No boot, diagnostic, or sequencing performance is established.

A meaningful verification requires specialist diagnostics and more than power-on.

High · Oem Support Horizon

PacBio states Sequel II/IIe support ends September 30, 2028.

Published lifecycle context shortens the remaining supported ownership window.

High · Heavy Logistics

The platform is approximately 798 lb / 362 kg and buyer-managed removal remains unresolved.

The logistics reserve is a decision-model assumption, not a quote.

High · Workflow Incomplete

Software, data environment, consumables, and site infrastructure are not confirmed.

A complete-looking cabinet is not a turnkey sequencing workflow.

Sources

View cited public sources